Amylx Pharmaceuticals Inc vs Tripadvisor Inc Common Stock — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Tripadvisor Inc Common Stock trades at $11.04 (market cap $1.28B). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2.1× Tripadvisor Inc Common Stock's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| AMLX | TRIP | |
|---|---|---|
Market Cap | $2.64B | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $19.14 |
52-Week Low | $7.82 | $9.24 |
Enterprise Value | $2.39B | $1.33B |
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →